| 2025-02-14 | +5.92 % |
|
| 2025-02-13 | +0.26 % |
|
| 2025-02-11 | -2.14 % |
|
| 2025-02-10 | +0.22 % |
|
| 2025-02-06 | -0.52 % |
|
| 2025-02-05 | +1.51 % |
|
| 2025-02-04 | +0.47 % |
|
| 2025-02-03 | +0.25 % |
|
| 2025-01-28 | +0.94 % |
|
| 2025-01-24 | +1.2 % |
|
| 2025-01-17 | -0.54 % |
|
| 2025-01-15 | +1.55 % |
|
| 2024-12-27 | -0.41 % |
|
| 2024-12-24 | +0.88 % |
|
| 2024-12-20 | +5.57 % |
|
| 2024-12-19 | +0.74 % |
|
| 2024-12-17 | +1.82 % |
|
| 2024-12-10 | +1.28 % |
|
| 2024-12-09 | +0.89 % |
|
| 2024-12-02 | +1.69 % |
|
| 2024-11-26 | +0.14 % |
|
| 2024-11-25 | +6.87 % |
|
| 2024-11-22 | -2.19 % |
|
| 2024-11-19 | -1.82 % |
|
| 2024-11-18 | +0.51 % |
|
| 2024-11-12 | +5.73 % |
|
| 2024-11-08 | +1.52 % |
|
| 2024-11-06 | -0.57 % |
|
| 2024-11-01 | -0.18 % |
|
| 2024-10-31 | -1.84 % |
|
| 2024-10-30 | -0.61 % |
|
| 2024-10-29 | +0.19 % |
- DexCom (DXCM) stock rose 0.19% as recent analyst reports indicate a mix of price target reductions and upgrades, reflecting continued positive sentiment towards the company's growth potential in the continuous glucose monitoring market.
The stock's increase can be attributed to the presence of multiple buy ratings from analysts despite some downward adjustments in price targets, suggesting confidence in the company's long-term prospects.
- DexCom (DXCM) stock increased by 0.19% as analysts issued mixed ratings, with some upgrading the stock while others lowered earnings forecasts, reflecting a generally positive outlook despite recent estimate adjustments.
The reason for DexCom's stock increase could be attributed to analysts maintaining a "buy" or "outperform" ratings and potential continued institutional investment interest, indicating confidence in the company's future performance.
- DexCom (DXCM) stock increased by 0.19% following Forsta AP Fonden's disclosure that it raised its position in the company by 16.6% in the third quarter, indicating positive investor sentiment and confidence in the stock.
- DexCom (DXCM) stock rose 0.19% after Wells Fargo & Company increased its price target for the company from $80.00 to $90.00, signaling strong investor confidence in the medical device firm.
- DexCom (DXCM) stock rose by 0.19% despite a price target reduction from Lehink Partners and mixed ratings from various analysts, indicating some investor confidence amid the fluctuations. The stock may have gone up due to overall positive sentiments from analysts, where the majority still maintain a buy rating and highlight the potential for growth despite recent target cuts.
- The article discusses a lawsuit against Acadia Healthcare Company, which alleges financial misrepresentations related to insurance fraud, impacting investor confidence and causing a drop in Acadia's stock price, while also highlighting a slight increase of 0.19% in Dexcom (DXCM) stock, possibly as a market reaction to broader movements in the healthcare sector or investor sentiment.
Dexcom's stock may have gone up due to its perceived stability amidst the negative news regarding Acadia Healthcare, attracting investors seeking safer options.
- DexCom, Inc. (DXCM) stock rose by 0.19% due to increased institutional investments, with significant share acquisitions from multiple investors like Forsta AP Fonden and Assenagon Asset Management, indicating a strong market interest in the company.
|
| 2024-10-28 | -1.82 % |
|
| 2024-10-25 | -1.88 % |
|
| 2024-10-24 | +3.27 % |
- Dexcom (DXCM) stock rose by 3.27% last night, likely due to positive market sentiment and advancements in its product offerings, although specific reasons for the increase were not detailed in the article.
- The article discusses various sports news, including updates on rugby squads, Gaelic games, and soccer matches, but it does not provide specific information on why Dexcom (DXCM) stock experienced a 3.27% increase.
The rise in Dexcom stock could be attributed to positive market sentiment, favorable news related to the company's performance or advancements, or broader trends in the healthcare sector. However, the article does not detail any specific reasons for this increase.
- The article discusses a positive turn in U.S. and global markets, led by a significant surge in Tesla's stock, which impacted overall investor sentiment and contributed to Dexcom (DXCM) stock rising by 3.27%.
Dexcom's stock likely went up due to the positive market sentiment stemming from strong corporate earnings reports, particularly from major companies like Tesla, and decreasing Treasury yields, which can lead to increased investor confidence in growth stocks.
- DexCom (DXCM) stock rose by 3.27% following Taylor Frigon Capital Management LLC's disclosure of a 51.6% increase in its stake in the company, indicating strong institutional confidence in DexCom.
- Dexcom (DXCM) stock rose 3.27% likely due to positive market sentiment around its performance amidst a broader mixed trading environment in equity markets, where certain tech and financial stocks were showing resilience and gains.
|
| 2024-10-23 | -0.82 % |
|
| 2024-10-22 | +0.65 % |
|
| 2024-10-21 | +0.32 % |
|
| 2024-10-18 | +4.07 % |
- DexCom (DXCM) stock rose by 4.07% following recent disclosures regarding institutional trading activity, particularly CX Institutional significantly reducing its holdings, alongside positive earnings results that topped expectations and an overall strong market interest in diabetes management solutions.
- DexCom, Inc. (DXCM) stock rose 4.07% after Swedbank AB increased its holdings in the company by 15.2%, acquiring an additional 28,289 shares in the third quarter, signaling growing investor confidence in the company's performance.
- The article discusses a class action lawsuit against DexCom, Inc. for allegedly misleading investors about its financial performance, yet the stock rose by 4.07% likely due to speculative investor optimism or broader market trends despite the legal issues faced by the company.
- DexCom (NASDAQ: DXCM) stock experienced a 4.07% increase due to significant institutional investment, as Exchange Traded Concepts LLC boosted its holdings by 39.5% and other firms also increased their stakes, reflecting positive investor sentiment and confidence in the company's growth prospects amidst favorable quarterly earnings reports and numerous buy ratings from analysts.
|
| 2024-10-17 | -0.5 % |
|
| 2024-10-16 | +4.17 % |
|
| 2024-10-15 | -3.01 % |
|
| 2024-10-14 | -0.04 % |
|
| 2024-10-11 | -0.5 % |
|
| 2024-10-10 | -0.09 % |
|
| 2024-10-09 | +0.27 % |
|
| 2024-10-08 | +1.18 % |
|
| 2024-10-07 | +0.75 % |
|
| 2024-10-03 | -2.12 % |
|
| 2024-10-02 | +1.67 % |
- DexCom (DXCM) stock rose by 1.67% despite a recent class action lawsuit and disappointing financial results that previously caused a significant drop in its share price. The increase in the stock price could be attributed to market corrections or investor sentiment following the news of the lawsuit, as it may create opportunities for future growth or settlements.
- DexCom (DXCM) stock rose by 1.67% following Brown Financial Advisors' acquisition of 10,902 shares during the second quarter, indicating growing institutional interest in the company.
- DexCom (DXCM) stock increased by 1.67% amid ongoing class action lawsuits involving the company and other stocks, likely due to investors responding positively to the legal notices as potentially providing an opportunity for recourse or compensation related to stock performance.
- The article discusses a securities class action being investigated against DexCom, Inc. (DXCM) by the law firm Faruqi & Faruqi LLP, which claims the company misled investors about its salesforce and growth potential, resulting in a significant drop in stock value earlier this year; however, despite this ongoing legal issue, Dexcom's stock rose by 1.67% likely due to market speculation or recovery interest from investors following its recent lows.
- DexCom (DXCM) stock rose by 1.67% despite being down 53% from its peak earlier this year, primarily because of concerns over reduced sales growth projections and increased competition in the continuous glucose monitoring (CGM) market, which have led to investor uncertainty about its future performance.
- The article discusses a class-action notice for DexCom (DXCM) shareholders following a significant drop in stock price after the company lowered its revenue guidance in July 2024; however, DexCom stock was reported to have increased by 1.67% recently, potentially due to market recovery or positive investor sentiment following recent updates or announcements.
|
| 2024-10-01 | -1.55 % |
|
| 2024-09-30 | -0.37 % |
|
| 2024-09-27 | -0.36 % |
|
| 2024-09-26 | +1.2 % |
|
| 2024-09-25 | -2.81 % |
|
| 2024-09-24 | -1.49 % |
|
| 2024-09-23 | -1.04 % |
|
| 2024-09-19 | +3.54 % |
- The article discusses a class action securities lawsuit filed against DexCom, Inc. for alleged securities fraud, following a significant drop in their stock price after disappointing financial results, yet despite this backdrop, the stock rose 3.54% recently, potentially due to market speculation or investor confidence rebounding.
- DexCom (DXCM) stock rose by 3.54% despite a lawsuit being filed against the company, likely due to market reactions to positive growth potential as the company works to expand its glucose monitoring systems and recover from a recent earnings setback that had previously depressed its stock price.
- The article discusses a securities class action investigation against DexCom, Inc. (NASDAQ:DXCM), where it highlights that the stock rose 3.54% amid ongoing legal issues and claims of misleading information regarding its sales force and financial performance. The recent uptick in DexCom's stock price may be attributed to investors reacting positively following the news of potential legal claims, which could prompt a reevaluation of the stock's position in the market.
- DexCom (DXCM) stock increased by 3.54% despite ongoing scrutiny from investors and analysts following a disappointing Q2 2024 earnings report and subsequent downgrades, as the market may be reacting to potentially oversold conditions or optimism about future recovery strategies.
- DexCom (DXCM) stock rose by 3.54% likely due to investor reactions to a class action lawsuit announcement concerning other companies, which may have redirected focus or created a more favorable sentiment for DexCom amidst its own recent challenges.
|
| 2024-09-18 | +0.75 % |
|
| 2024-09-17 | -1.64 % |
|
| 2024-09-16 | +0.83 % |
|
| 2024-09-13 | +1 % |
|
| 2024-09-12 | +0.51 % |
|
| 2024-09-11 | -0.12 % |
- Dexcom (DXCM) stock is down by 0.12% due to a recent insider sale of shares by an executive, which, while routine for tax purposes, can sometimes raise investor concerns about executive confidence, coupled with increased competition from Abbott's new continuous glucose monitoring product.
- DexCom, Inc. (DXCM) stock has experienced a downturn following the announcement of a lawsuit against the company and its executives, amid disappointing second-quarter earnings and a downward revision of revenue guidance for the year, which contributed to a significant decline in stock price.
- Dexcom Inc (NASDAQ:DXCM) stock was down by 0.12% following the sale of shares by CFO Jereme M. Sylvain as part of a tax obligation transaction, which could raise concerns among investors about insider sentiment towards the company's valuation and future prospects amidst a competitive market environment.
- DexCom (DXCM) stock declined 0.12% amid the announcement of a class action lawsuit related to alleged securities fraud following a significant drop in its stock price after the company reduced its revenue guidance for 2024 due to disappointing performance on key strategic initiatives.
- DexCom (DXCM) stock was down by 0.12% following reports of a class action lawsuit linked to its disappointing financial results and reduced revenue guidance announced on July 25, 2024, which were attributed to the failure of key strategic initiatives.
- Dexcom (DXCM) stock experienced a slight decline of 0.12% following the sale of 746 shares by Executive Vice President Jacob Steven Leach for tax-related reasons, reflecting an insider transaction that may raise concerns about executive confidence among investors.
|
| 2024-09-10 | -1.66 % |
|
| 2024-09-09 | +1.6 % |
|
| 2024-09-06 | -0.64 % |
|
| 2024-09-05 | -1.1 % |
|
| 2024-09-04 | -3.51 % |
|
| 2024-09-03 | +4.36 % |
|
| 2024-08-30 | -0.4 % |
|
